ViroGates gives notice to convene an Extraordinary General Meeting on 21 May 2025

BIRKERØD, DENMARK – ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring chronic inflammation in health clinics and hospitals, hereby convenes an Extraordinary General Meeting to be held on Wednesday, 21 May 2025, at 4:00 pm.
The meeting will be at the company's address at Banevænget 13, 3460 Birkerød. The agenda, full proposals, and registration details are on the company’s website.

For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: [email protected]

Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: [email protected]

About ViroGates
ViroGates A/S is an international medical technology company that develops and markets blood tests to measure chronic inflammation in health clinics and improve hospital patient care. ViroGates markets its blood test products under the suPARnostic® brand.

The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (ticker “VIRO”) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.